";s:4:"text";s:5187:" In a pharmacokinetic study, subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh classification C, which included bilirubins about 2-11 times ULN with minimal to severe ascites) had two-fold increase in exposure (AUC) and 47% reduction in systemic clearance. 1990 Aug;11(8):309-10. doi: 10.1016/0165-6147(90)90229-2.BMC Complement Altern Med. In the extended adjuvant setting, the reported drug-related adverse reactions that were significantly different from placebo were hot flashes, arthralgia/arthritis, and myalgia.Based on a median follow-up of patients for 28 months, the incidence of clinical fractures from the core randomized study in patients who received Femara was 5.9% (152) and placebo was 5.5% (142). All of these patients were in Option 1. In each study over 60% of the patients had received therapeutic antiestrogens, and about one-fifth of these patients had an objective response. femhrt (0.5 mg/2.5 mcg): Each oval white tablet contains 0.5 mg norethindrone acetate and 2.5 mcg ethinyl estradiol. Moderate decreases in lymphocyte counts, of uncertain clinical significance, were observed in some patients receiving Femara 2.5 mg. Clipboard, Search History, and several other advanced features are temporarily unavailable.
About 1/3 of the patients were greater than or equal to 70 years old. The following adverse reactions were also identified in less than 5% of the 2049 patients treated with letrozole and not included in the table: fall, vertigo, hyperbilirubinemia, jaundice, and chest pain.In study MA-17, the median duration of extended adjuvant treatment was 24 months and the median duration of follow-up for safety was 28 months for patients receiving Femara and placebo.Table 3 describes the adverse reactions occurring at a frequency of at least 5% in any treatment group during treatment. Selected baseline characteristics for each study are shown in Table 16.Confirmed objective tumor response (complete response plus partial response) was the primary endpoint of the trials.